Pfizer’s Rimegepant Trial Targets Chronic Migraine Market Upside

Pfizer (PFE) completed a Phase 1 study for PF-07799544, an experimental oral drug. The study, focused on drug movement and clearance in healthy men, was completed on 2026-09-18. This milestone clears a key safety and dosing step before larger trials, supporting Pfizer's long-term pipeline.

Pfizer (PFE) will share additional revenue with the U.S. HHS if it raises drug prices internationally. The company offers a 6.22% dividend yield, trades 4.6% above its GF Value™ of $26.45, and has a GF Score™ of 75/100. Insiders have shown confidence with net buying of $3.0 million over the past year.

Pfizer (PFE) will share a portion of its increased international drug revenue with the U.S. Department of Health and Human Services, according to Bloomberg. The agreement, effective from 2026 to 2029, applies to currently marketed medicines.

Pfizer's oncology sales rose 3% to $4.17B in Q2 2026, driven by Padcev, Lorbrena, and Braftovi/Mektovi. Padcev sales increased 23% to $667M, benefiting from market share gains. J&J's oncology revenues grew 16.9% to $14.4B in H1 2026, led by Darzalex and Erleada. Zacks' EPS estimates for Pfizer increased slightly.

Pfizer will share overseas drug revenue with the U.S. HHS under a 'most favored nation' pricing deal from 2026 to 2029, according to Bloomberg. The agreement, part of efforts to lower U.S. drug prices, involves sharing revenue from higher overseas prices. Details like the percentage of revenue and covered medicines were redacted. Public Citizen released the contract via a FOIA lawsuit. Eli Lilly's separate agreement was also disclosed, but many others remain confidential.

The Trump administration will expand its Medicaid most-favored-nation drug pricing model to all 50 states, D.C., and Puerto Rico. The plan aims to lower drug prices by offering rates comparable to other developed nations. Deals have been signed with major drugmakers like Pfizer, Eli Lilly, and Novo Nordisk, as well as smaller biotechs.